CALC is trading 6.8% down at $0.92 as the stock undergoes a pullback following a significant multi-day rally. The decline follows a strong two-day surge where the price climbed from $0.63 to $0.99 during regular trading sessions.
- New regulatory filings on June 29, 2026, revealed that Chief Medical Officer Sudarshan Hebbar and Chief Business Officer Eric W. Roberts acquired a total of 311,215 shares on June 25, 2026, at $0.8033 per share.
- These acquisitions follow a private placement financing for up to approximately $49 million announced on June 24, 2026, to advance CalciMedica's pulmonary hypertension program.
- The after-hours price action appears to be driven by normal market volatility and profit-taking after recent sharp gains, alongside the newly disclosed insider transactions.